Abstract: Disclosed are novel compounds, novel compositions, methods of their use, and methods of their manufacture, where such compounds of Formula 1 are pharmacologically useful inhibitors of Protein Tyrosine Phosphatases (PTPase's) including PTP1B, T cell PTP, wherein n, m, X, R1, R2, R3, R4, R5, R6, and R7 are defined more fully in the description. The compounds are useful in the treatment of type I diabetes, type II diabetes, impaired glucose tolerance, insulin resistance, obesity, and other diseases.

Abstract: The present invention relates to compounds, compositions containing them, and their use for treating medical disorders resulting from a deficiency in growth hormone.

Abstract: Compounds of peptide mimetic nature having the general formula I ##STR1## wherein a and b are independently 1 or 2, R.sup.1 and R.sup.2 are independently H or C.sub.1-6 alkyl, G and J are independently, inter alia, aromats, and D and E are independently several different groups are growth hormone secretagogous with improved bioavailability.

Abstract: Compounds of the general formula I ##STR1## compositions containing them, and their use for treating medical disorders resulting from a deficiency in growth hormone are described.

Abstract: A compound of formula (I). ##STR1## The present invention relates to thereutically active carbazole derivatives, a method of preparing the same and to pharmaceutical compositions comprising the compounds. The novel compounds are useful in treating a central nervous system ailment related to the inhibition of GABA uptake via the GAT-4 subtype carrier.

Abstract: There are disclosed novel synthetic peptides of formula (I) ##STR1## where A, B, D, E, F, G, J, m, n, and p are defined in the specification. Compounds of formula (I) promote the release of growth hormone in humans and animals. Growth promoting compositions containing such compounds of formula (I) as the active ingredient, methods of stimulating the release of growth hormone, and the use of such compounds of formula (I) are also disclosed.

Abstract: Compounds of peptide mimetic nature having the general formula I ##STR1## wherein a and b are independently 1 or 2, R.sup.1 and R.sup.2 are independently H or C.sub.1-6 alkyl, G and J are independently, inter alia, aromats, and D and E are independently several different groups are growth hormone secretagogous with improved bioavailability.

Abstract: Novel peptide derivatives, compositions containing them, and their use for treating medical disorders resulting from a deficiency in growth hormone are disclosed. These peptide derivatives have the formula:A--B--C--D--E (--F).sub.pwherein A, B, C, D, E, F and p are as defined in the specification. These peptides exhibit improved resistance to proteolytic degradation as well as improved growth hormone releasing activity.

Abstract: Compounds of the formula A--B--C--D(--E).sub.p are used to stimulate the release of growth hormone from the pituitary.

Abstract: The present invention relates to compounds of formula I ##STR1## wherein X is amino, C.sub.1-6 -alkylamino, di-C.sub.1-6 -alkylamino;R.sup.1 is H, straight or branched C.sub.1-6 -alkyl or trifluoromethyl; R.sup.4 is H or straight or branched C.sub.1-6 -alkyl; or R.sup.1 and R.sup.4 together form a cyclobutyl, cyclopentyl or cyclohexyl ring;Y is O, S, SO.sub.2, N--H or N-alkyl;R.sup.5 is selected from optionally substituted heterocycles;R.sup.6 is hydrogen, benzoyl or C.sub.1-6 -alkanoyl andR.sup.7 is hydrogen, benzoyl or C.sub.1-6 -alkanoyl; ora pharmaceutically acceptable salt thereof.The compounds have been found useful for treating central nervous system and cardiovascular ailments.

Abstract: A compound of formula (I), or a pharmaceutically acceptable salt thereof: ##STR1## wherein X is hydrogen, amino, halogen, hydroxy, lower alkoxy or lower alkyl andR.sup.1 is ##STR2## wherein Y is methylene or a valence bond, R.sup.2 and R.sup.5 is H or lower, straight or branched alkyl,R.sup.3 is H or lower alkyl, orR.sup.2 and R.sup.3 can together form a cyclobutyl, cyclopentyl, cyclohexyl or phenyl ring,Z is oxygen, methylene, sulphur, sulphonyl or a valence bond,R.sup.4 is H, lower alkyl, aralkyl, a mono or bicyclic aromatic system optionally substituted with various groups.The compounds have been found useful for treating central nervous system ailments.

Abstract: The present invention relates to therapeutically active azaheterocyclic compounds, a method of preparing the same and to pharmaceutical compositions comprising the compounds. The novel compounds are useful in treating a central nervous system ailment related to the GABA uptake.

Abstract: The present invention relates to therapeutically active azaheterocyclic compounds, a method of preparing the same and to pharmaceutical compositions comprising the compounds. The novel compounds are useful in treating a central nervous system ailment related to the GABA uptake.

Abstract: The present invention relates to therapeutically active azaheterocyclic compounds, a method of preparing the same and to pharmaceutical compositions comprising the compounds. The novel compounds are useful in treating a central nervous system ailment related to the GABA uptake.

Abstract: The present invention relates to therapeutically active azaheterocyclic compounds, a method of preparing the same and to pharmaceutical compositions comprising the compounds. The novel compounds are useful in treating a central nervous system ailment related to the GABA uptake.

Abstract: A compound of formula (I), or a pharmaceutically acceptable salt thereof: ##STR1## wherein X is halogen, amino, perhalomethyl, cyano, C.sub.1-6 -alkoxy, C.sub.1-6 -alkylthio or C.sub.1-6 -alkylamino;A is methyl, halomethyl, cyanomethyl, aminomethyl, vinyl, methylthiomethyl or methoxymethyl;R.sup.1 is selected from optionally substituted N-bonded heterocyclics.The compounds have been found useful for treating central nervous system ailments.

Abstract: This application relates to methods of treating myocardial or cerebral ischemia, comprising administering a compound of formula I: ##STR1## wherein X is halogen, perhalomethyl, cyano, C.sub.1-6 -alkoxy, C.sub.1-6 -alkylthio or C.sub.1-6 -alkylamino; andR.sup.1 is selected from N-bonded heterocycles.The compound with the greatest ability to discriminate between the A1 and A2 adenosine receptors is 2-chloro-N-[4-phenoxy-1-piperidinyl]adenosine.

Abstract: A compound of formula (I), or a pharmaceutically acceptable salt thereof: ##STR1## wherein X is halogen, trifluoromethyl, cyano, C.sub.1-6 -alkoxy, C.sub.1-6 -alkylthio, C.sub.1-6 -alkylamino or C.sub.1-6 -dialkylamino;R.sup.1 and R.sup.4 are H or straight or branched C.sub.1-6 -alkyl or trifluoromethyl or R.sup.1 and R.sup.4 together form a cycloalkyl ring;Y is O, S, SO.sub.2, NH or N-alkyl;R.sup.5 is selected from optionally substituted heterocycles.R.sup.6 and R.sup.7 are hydrogen, benzoyl or C.sub.1-6 -alkanoyl.The compounds have been found useful for treating central nervous system and cardiovascular ailments.

Abstract: A compound of formula (I), or a pharmaceutically acceptable salt thereof: ##STR1## wherein X is halogen, perhalomethyl, cyano, C.sub.1-6 -alkoxy, C.sub.1-6 -alkylthio, or C.sub.1-6 -alkylamino; andR.sup.1 is selected from N-bonded heterocycles.The compound with the greatest ability to discriminate between the A1 and A2 adenosine receptors is 2-chloro-N-[4-phenoxy-1-piperidinyl]adenosine. These adenosine derivatives are useful as anti-convulsants.

Abstract: Adenosine compounds having the following structure ##STR1## wherein X is halogen, perhalomethyl, acetamido, cyano, C.sub.1-6 -alkoxy, C.sub.1-6 -alkylthio or C.sub.1-6 -alkylamino; andR.sup.1 is --NR.sup.2 R.sup.3 or YR.sup.4, wherein Y is oxygen or sulfur;R.sup.2 is phenyl, C.sub.1-6 -alkyl or substituted C.sub.1-6 -alkyl; andR.sup.4 is naphthyl, partly saturated naphthyl; optionally phenyl or phenoxy substituted C.sub.1-6 -alkyl wherein the phenyl and phenoxy substituents are also optionally substituted, or optionally phenyl or phenoxy substituted C.sub.3-8 -cycloalkyl and their pharmaceutically acceptable salts are useful in the treatment of myocardial and cerebral ischemias.